ArticleRheumatology (Oxford, England)2025
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Difficult-To-Manage Axial Spondyloarthritis: Bridging Consensus Definitions and Real-World Practice.International journal of rheumatic diseases · 2026Article
- Tumor necrosis factor inhibitor prescribing and persistence by specialty in radiographic axial spondyloarthritis: a Korean claims study.The Korean journal of internal medicine · 2026Article
- Article
- Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.EULAR rheumatology open · 2026Article
- Year in Review: Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
- Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.Frontiers in pharmacology · 2026Review
- Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort.Archives of rheumatology · 2025Article
- Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope.Rheumatology advances in practice · 2025Review
- Expert recommendations regarding the use of fecal calprotectin in daily clinical practice: statements of a taskforce process from the Hellenic Group for the Study of Inflammatory Bowel Disease (EOMIFNE).Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.